Trial Profile
A Single Arm, Multicenter Phase II Trial of RAD001 as Monotherapy in the Treatment of Advanced Papillary Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms RAPTOR
- Sponsors Novartis Pharma
- 24 Sep 2016 Results of final analysis published in the European Journal of Cancer.
- 16 Jan 2015 Status changed from active, no longer recruiting to completed, according to ClinicalTrial.gov record.
- 08 May 2014 Planned End Date changed from 1 Feb 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.